vTv Therapeutics’ (VTVT) “Buy” Rating Reiterated at BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $57.00 target price on the biotechnology company’s stock. BTIG Research’s price objective indicates a potential upside of 101.91% from the stock’s current price.

VTVT has been the topic of several other reports. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. HC Wainwright decreased their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Zacks Research upgraded vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Finally, Rodman & Renshaw started coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $28.23 on Wednesday. The firm’s fifty day moving average is $31.90 and its two-hundred day moving average is $33.55. The firm has a market cap of $111.23 million, a price-to-earnings ratio of -26.63 and a beta of 0.21. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, equities research analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.